TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31331699

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day for up to 1 year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Methotrexate-vinblastine (vinblastine 5 mg/m2 per dose and methotrexate 30 mg/m2 per dose, administered weekly for 6 months and then every other week for 6 months)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 72

Group type: COMPARATOR
Intervention: Methotrexate-vinblastine
Number of subjects: 72
Study: 29282088

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (4 cycles of FLOT chemotherapy)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by surgical resection of primary and metastases
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Chemotherapy with trastuzumab if Her2+ (4 cycles)
Number of subjects: 271
Study: 25301758

Group type: EXPERIMENTAL
Intervention: Mitomycin C plus BCG
Number of subjects: 407

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 407
Study: 25092377

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22745533

Group type: EXPERIMENTAL
Intervention: COPE-active intervention (standardized physiotherapeutic reactivation intervention)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study: 19181719

Group type: COMPARATOR
Intervention: Speed-of-processing training
Number of subjects: 2014

Group type: EXPERIMENTAL
Intervention: No-contact control
Number of subjects: 2014
Study: 18654123

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 190
Study: 16340383

Group type: EXPERIMENTAL
Intervention: 750 mg/day valproate
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 75 mg/day topiramate
Number of subjects: 49
Study: 11904609

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol at 6‐hour intervals
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol at 6‐hour intervals
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol followed by 200 microg at 6‐hour intervals
Number of subjects: 150
Study: 10447786

Group type: EXPERIMENTAL
Intervention: One-legged exercise training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Two-legged exercise training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both training regimens
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: One-legged training
Number of subjects: 16
Study: 7818151

Group type: EXPERIMENTAL
Intervention: Whole-body warming and cooling
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Whole-body rewarming
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Whole-body cooling
Number of subjects: 56
Study: 2256579

Group type: EXPERIMENTAL
Intervention: High Group I allergenic house dust (8.4 micrograms/g)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low Group I allergenic house dust (0.66 micrograms/g)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Natural exposure to house dust
Number of subjects: 19
Study: 254678

Group type: EXPERIMENTAL
Intervention: Family centered nursing approach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Staff nurse‐patient relationship prior to transfer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 31906999

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Increased H1-antihistamine dose (twofold)
Number of subjects: 150
Study: 30265341

Group type: EXPERIMENTAL
Intervention: E-cigs with 10% of labeled propylene glycol (PG), glycerol (G), and nicotine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Smokers smoking 10 non-filter cigarettes spiked with labeled PG, G, and nicotine
Number of subjects: 25
Study: 28350412

Group type: EXPERIMENTAL
Intervention: Structured sexual rehabilitation programme (30-min individualized session)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 68
Study: 26515383

Group type: COMPARATOR
Intervention: High Intensity (HI) exercise
Number of subjects: 277

Group type: COMPARATOR
Intervention: Low-to-Moderate Intensity (LMI) exercise
Number of subjects: 277
Study: 23398595

Group type: EXPERIMENTAL
Intervention: Hormonal treatment plus radiotherapy
Number of subjects: 875

Group type: COMPARATOR
Intervention: Hormonal treatment alone
Number of subjects: 875
Study: 21281668

Group type: EXPERIMENTAL
Intervention: Fitness
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fatness
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Executive function, mathematics and reading achievement, and parent ratings of child behavior
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Teacher ratings
Number of subjects: 170
Study: 19103990

Group type: EXPERIMENTAL
Intervention: Crush stenting
Number of subjects: 350

Group type: COMPARATOR
Intervention: Provisional side-branch T-stenting
Number of subjects: 350
Study: 17805061

Group type: EXPERIMENTAL
Intervention: Induction carboplatin (AUC = 5.5) on days 1 and 22, vinorelbine (25 mg/m2) on days 1, 8, 22, and 29, followed by intravenous topotecan (0.5 mg/m2) on days 43 to 47, days 57 to 61, and days 71 to 75 with accelerated radiotherapy (RT) at 2 Gy per fraction, twice daily for five consecutive days, every other week, to a cumulative dose of 60 Gy during a 5-week period.
Number of subjects: 35
Study: 15087615

Group type: EXPERIMENTAL
Intervention: BIS guided
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AAI guided
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 11310690

Group type: EXPERIMENTAL
Intervention: IV tubing replaced within 3 days
Number of subjects: 512

Group type: COMPARATOR
Intervention: IV tubing replaced within 4 to 7 days
Number of subjects: 512
Study: 9065294

Group type: EXPERIMENTAL
Intervention: Decontamination with polymyxin B (100 mg), tobramycin (80 mg), vancomycin (125 mg), and amphotericin B (500 mg) four times per day orally from the day before the operation until the seventh postoperative day
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Decontamination
Number of subjects: 205
Study: 7930223

Group type: EXPERIMENTAL
Intervention: Multifactor risk reduction program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 2906153

Group type: EXPERIMENTAL
Intervention: m-chlorophenyl-piperazine (MCPP) (0.25 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31206225

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28937706

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg
Number of subjects: 181
Study: 26558530

Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 1018
Study: 23791894

Group type: EXPERIMENTAL
Intervention: Eugenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvacrol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eugenol and Carvacrol
Number of subjects: 0
Study: 21377140

Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 0
Study: 17713847

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 50
Study: 16735583

Group type: EXPERIMENTAL
Intervention: Helmet and shoulder pads
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Helmet removal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Shoulder pads
Number of subjects: 16
Study: 14528504

Group type: EXPERIMENTAL
Intervention: lenercept 0.01 mg/kg (maximum 1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lenercept 0.05 mg/kg (maximum 5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lenercept 0.2 mg/kg (maximum 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lenercept 0.5 mg/kg (maximum 50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 11106679

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascorbic acid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curing H. pylori infection
Number of subjects: 0
Study: 9358690

Group type: EXPERIMENTAL
Intervention: Alcohol ascending limb (AAL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alcohol descending limb (ADL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sober control groups
Number of subjects: 60
Study: 1525531

Group type: EXPERIMENTAL
Intervention: Advice from general practitioners
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no advice)
Number of subjects: 154
Study: 4070320

Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg 3-times daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: clofibrate (500 mg 3-times daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 30003477

Group type: EXPERIMENTAL
Intervention: Theory-based online intervention with autonomy support and implementation intention components
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (received national guidelines, e-mail summary, and SMS messages)
Number of subjects: 202
Study: 28077825

Group type: EXPERIMENTAL
Intervention: Inhalation of essential oil for 3 minutes at a distance of approximately 10 cm from the nose, with aroma stone beside head (within 30 cm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inhalation of essential oil
Number of subjects: 60
Study: 24439348

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza (TIV)
Number of subjects: 669695

Group type: EXPERIMENTAL
Intervention: Tetanus-diphtheria
Number of subjects: 669695

Group type: EXPERIMENTAL
Intervention: Hepatitis B
Number of subjects: 669695

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella (MMR)
Number of subjects: 669695

Group type: EXPERIMENTAL
Intervention: Varicella
Number of subjects: 669695

Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 669695
Study: 22859346

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 22

Group type: COMPARATOR
Intervention: DMARD
Number of subjects: 22
Study: 20398112

Group type: EXPERIMENTAL
Intervention: Low-low beds introduced in intervention wards (1 low-low bed for every 12 beds)
Number of subjects: 10937

Group type: EXPERIMENTAL
Intervention: Low-low beds introduced in intervention wards
Number of subjects: 10937
Study: 18474113

Group type: EXPERIMENTAL
Intervention: Cooling treatment (hand inserted into a rigid chamber with subatmospheric pressure and cooled metal surface at 18-22 degrees C)
Number of subjects: 10
Study: 15841739

Group type: EXPERIMENTAL
Intervention: Higher dose (400/1000)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lower dose (200/500)
Number of subjects: 126
Study: 12683265

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive monitoring and warning about side effects
Number of subjects: 0
Study: 10921468

Group type: COMPARATOR
Intervention: Loratadine (0.3 mg/kg)
Number of subjects: 28
Study: 8885114

Group type: EXPERIMENTAL
Intervention: LTG + PHT
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG + PB
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG + CBZ
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG mono
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG + VPA + PHT
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG + VPA + CBZ
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG + VPA + PB
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG + VPA
Number of subjects: 302

Group type: COMPARATOR
Intervention: LTG monotherapy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: LTG with VPA
Number of subjects: 302
Study: 1577042

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cavinton
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of ADP with either adrenaline or PAF, adrenaline with PAF, and collagen with ADP
Number of subjects: 0
Study: 6714601

Group type: EXPERIMENTAL
Intervention: 30-cm flexible sigmoidoscope
Number of subjects: 96

Group type: COMPARATOR
Intervention: 60-cm flexible sigmoidoscope
Number of subjects: 96
Study: 31205211

Group type: EXPERIMENTAL
Intervention: Thawed plasma (5‐day shelf life)
Number of subjects: 7275

Group type: EXPERIMENTAL
Intervention: Thawed plasma
Number of subjects: 7275

Group type: EXPERIMENTAL
Intervention: Thawed plasma program implementation
Number of subjects: 7275
Study: 29224648

Group type: EXPERIMENTAL
Intervention: High-dose oral multivitamins and multiminerals (6 tablets daily)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo (6 tablets daily)
Number of subjects: 460
Study: 27056776

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) of 0
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) >0 to 4
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) >4 to 8
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) >8
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: SYNTAX revascularization index (SRI) 100%
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: SYNTAX revascularization index (SRI) 50% to <100%
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: SYNTAX revascularization index (SRI) 0 to <50%
Number of subjects: 427
Study: 25440203

Group type: EXPERIMENTAL
Intervention: Standard physiotherapy treatment accompanied by 20min knee joint distraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard physiotherapy treatment alone
Number of subjects: 40
Study: 22508468

Group type: EXPERIMENTAL
Intervention: MTX plus etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step-up from MTX monotherapy to combination therapy
Number of subjects: 0
Study: 20729667

Group type: EXPERIMENTAL
Intervention: Onyx HD‐500
Number of subjects: 13
Study: 17908710

Group type: EXPERIMENTAL
Intervention: Lung elastic recoil measured at total lung capacity (CR)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lung elastic recoil measured at functional residual capacity (CRfrc)
Number of subjects: 67
Study: 11340222

Group type: EXPERIMENTAL
Intervention: Functional MRI in patients after stroke
Number of subjects: 28

Group type: COMPARATOR
Intervention: Functional MRI in healthy control subjects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Geometric center of activation of the primary sensorimotor cortex in patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Geometric center of activation of the primary sensorimotor cortex in patients with hand-tapping task
Number of subjects: 28
Study: 9116988

Group type: EXPERIMENTAL
Intervention: Serum β-carotene concentration
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Serum retinol concentration
Number of subjects: 816
Study: 8317392

Group type: EXPERIMENTAL
Intervention: Fish oil (64 mg n‐3 fatty acids/kg body wt)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 8
Study: 3107027

Group type: EXPERIMENTAL
Intervention: Active diazepam (Group D)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 42
Study: 29697587

Group type: EXPERIMENTAL
Intervention: Video-streamed group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Light microscopy group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Virtual microscopy group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 67
Study: 27242368

Group type: COMPARATOR
Intervention: Standard azathioprine maintenance therapy (1.5-2.0 mg/kg until 1 year after diagnosis, then tapering to 25 mg every 3 months)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Extended azathioprine maintenance therapy (1.5-2.0 mg/kg continued until 4 years after diagnosis, then tapered)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard azathioprine maintenance therapy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Extended azathioprine maintenance therapy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: C-ANCA positive patients at remission
Number of subjects: 131
Study: 23604701

Group type: EXPERIMENTAL
Intervention: Hexitol-sweetened gum containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pentitol-sweetened gum containing no CPP-ACP
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group with no gum
Number of subjects: 130
Study: 23564917

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (40% of total diet energy content as carbohydrates)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control diet (55% of total diet energy content as carbohydrates)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 152
Study: 20511044

Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (ACI)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Osteoarticular Transplantation (OATS)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Return to preinjury level of sports
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Defect size < 2 cm², preoperative symptoms < 18 months, no prior surgery, younger age, higher sports level
Number of subjects: 658

Group type: COMPARATOR
Intervention: Return to sports performance
Number of subjects: 658
Study: 18420532

Group type: EXPERIMENTAL
Intervention: Midazolam (8 mg) after 28 days of GBE administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (8 mg) before GBE administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (8 mg) after GBE administration
Number of subjects: 0
Study: 15885510

Group type: EXPERIMENTAL
Intervention: Corrective Feedback (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Errorless Learning (EL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Administration (SA)
Number of subjects: 0
Study: 12651681

Group type: EXPERIMENTAL
Intervention: Acoustic puncture assist device
Number of subjects: 60
Study: 11198369

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1087
Study: 8636834

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Higher cognitive complexity
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 112
Study: 1735149

Group type: EXPERIMENTAL
Intervention: Invasive strategy (INV)
Number of subjects: 3339

Group type: COMPARATOR
Intervention: Conservative strategy (CON)
Number of subjects: 3339
Study: 31356705

Group type: EXPERIMENTAL
Intervention: Electronic apex locators
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 64
Study: 28844986

Group type: EXPERIMENTAL
Intervention: Service dogs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotional support dogs
Number of subjects: 0
Study: 25962611

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) using hyperbaric bupivacaine 9 mg with fentanyl 15 µg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intravenous analgesia (IVA) using remifentanil infusion 0.1 µg kg min(‐1)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control (no anaesthetic intervention)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) for re-attempts
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intravenous analgesia (IVA) for re-attempts
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intravenous analgesia (IVA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) and IVA
Number of subjects: 189
Study: 23820501

Group type: EXPERIMENTAL
Intervention: OCA regimen (omeprazole 20mg, clarithromycin 500mg, amoxicillin 1g)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: OMAB regimen (omeprazole 20mg, metronidazole 500mg, amoxicillin 1g, bismuth subcitrate 240mg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both OCA and OMAB regimens
Number of subjects: 93
Study: 23090161

Group type: EXPERIMENTAL
Intervention: Postfire forearm immersion in 10 °C water
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Live-fire exposure
Number of subjects: 94
Study: 19232611

Group type: EXPERIMENTAL
Intervention: dydrogesterone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: calcium plus vitamin D
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 18381950

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily (unblinded extension)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 15765179

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Conventional medical management)
Number of subjects: 60